Welcome to our dedicated page for Outlook Therapeutics news (Ticker: OTLKW), a resource for investors and traders seeking the latest updates and insights on Outlook Therapeutics stock.
News for OTLKW reflects developments at Outlook Therapeutics, Inc., a biopharmaceutical company concentrated on ONS-5010/LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma), an ophthalmic formulation of bevacizumab for retinal diseases such as wet age-related macular degeneration (wet AMD). Company news frequently reiterates this focus on enhancing or optimizing the standard of care for bevacizumab in retina indications.
Readers can expect coverage of regulatory milestones, including interactions with the U.S. Food and Drug Administration (FDA) around the Biologics License Application (BLA) for ONS-5010. Recent announcements have described complete response letters, Type A meetings, BLA resubmissions, and FDA acknowledgments of resubmissions as complete, along with associated Prescription Drug User Fee Act (PDUFA) goal dates. These updates provide context on the regulatory pathway for the investigational product in the United States.
The OTLKW news feed also includes information on European commercialization of LYTENAVA™ (bevacizumab gamma), where Outlook Therapeutics reports that the product has received Marketing Authorization from the European Commission and the UK MHRA for the treatment of wet AMD and has been launched commercially in Germany and the UK. News items describe initial sales into distribution channels, early prescribing trends, and efforts to expand into additional European markets, subject to pricing and reimbursement approvals in certain Member States.
Additional news topics include corporate and investor events, such as participation in healthcare conferences, presentations at ophthalmology-focused meetings, and the appointment of senior executives in corporate strategy and business development. Disclosures on stock option grants to new employees as employment inducement awards may also appear. For investors and observers following OTLKW, this news page offers a centralized view of Outlook Therapeutics’ reported clinical, regulatory, commercial, and corporate developments related to its ophthalmic bevacizumab program.
Outlook Therapeutics (OTLK) announced that the FDA has requested more information to complete its Biologics License Application (BLA) for ONS-5010 (bevacizumab-vikg) for treating wet age-related macular degeneration. The company voluntarily withdrew the BLA and aims to resubmit a revised application by September 2022. CEO Russell Trenary expressed confidence in the product's potential to be the first FDA-approved ophthalmic formulation of bevacizumab. ONS-5010 is designed to offer a safer alternative to unapproved repackaged formulations used in current treatments for retinal diseases.
Outlook Therapeutics, a pre-commercial biopharmaceutical company, will present at the H.C. Wainwright Global Investment Conference from May 23-26, 2022, in Miami, FL. The company is focused on developing ONS-5010/LYTENAVA™, an investigational therapy aimed at being the first FDA-approved ophthalmic formulation of bevacizumab for retinal indications. The presentation will be led by Lawrence Kenyon, Chief Financial Officer, with opportunities for one-on-one meetings with investors. A video webcast of the presentation will be available on May 24, 2022.
Outlook Therapeutics (Nasdaq: OTLK) has submitted a Biologics License Application (BLA) for ONS-5010, branded as LYTENAVA™, for treating wet age-related macular degeneration (AMD). The company anticipates a PDUFA date announcement in June 2022 and is ramping up pre-launch plans, supported by sufficient funding. Financial results for Q2 2022 show a net loss of $19.7 million, compared to $13.1 million in the previous year, with cash reserves at $58.4 million. Outlook is optimistic about commercial partnerships and aims for global market registration.
Outlook Therapeutics (Nasdaq: OTLK) announced that COO Terry Dagnon will participate in the Retina World Congress 2022 from May 12-15 in Fort Lauderdale, Florida. Dagnon will discuss ONS-5010 (LYTENAVA™), an investigational formulation of bevacizumab for retinal diseases, including wet AMD. The FDA has received a Biologics License Application (BLA) for ONS-5010, which, if approved, would provide 12 years of marketing exclusivity. This product aims to address safety concerns related to off-label IV use of bevacizumab currently prevalent in the retina community.
Outlook Therapeutics (Nasdaq: OTLK) announced a live moderated video webcast on May 11, 2022, at 1:00 PM ET. President & CEO Russ Trenary will provide a corporate overview and discuss their investigational therapy, ONS-5010/LYTENAVA™, which targets retinal conditions like wet AMD. Investors can submit questions during the event. A webcast will be accessible on their website, with a replay available for 90 days. The company aims for ONS-5010 to be the first FDA-approved ophthalmic formulation of bevacizumab for retinal indications.
Outlook Therapeutics (OTLK) announced a reorganization of BioLexis, its strategic shareholder, which will be renamed Tenshi Healthcare Pte Limited. The reorganization enhances GMS Holdings' position, allowing for direct ownership of Outlook Therapeutics shares. Outlook Therapeutics has submitted a Biologics License Application (BLA) for its investigational therapy ONS-5010 (bevacizumab-vikg) to the FDA, marking a key milestone for the company. This submission is supported by three completed clinical trials aimed at treating retinal diseases.
Outlook Therapeutics (Nasdaq: OTLK) announced that CEO Russ Trenary will present at the Wet AMD and DME Drug Development Summit from April 5-7, 2022, in Boston, Massachusetts. His session, titled Enhancing the Standard of Care in Wet AMD, BRVO, & DME, is scheduled for April 6, 2022, at 9:45 AM EST. The company aims to launch ONS-5010/LYTENAVA™, the first FDA-approved ophthalmic formulation of bevacizumab for retinal diseases, supported by three clinical trials. If approved, ONS-5010 will be available in multiple global markets.
Outlook Therapeutics has submitted its Biologics License Application (BLA) to the FDA for ONS-5010, branded as LYTENAVA™ (bevacizumab-vikg), targeting wet age-related macular degeneration (wet AMD). If approved, it will be the first FDA-approved ophthalmic formulation of bevacizumab. This submission is bolstered by positive results from the NORSE clinical trials, which demonstrated significant vision improvement and a favorable safety profile. The company anticipates marketing approval by late 2022 or early 2023, aiming to replace unapproved IV bevacizumab.
Outlook Therapeutics has appointed Alicia Tozier as Senior Vice President of Marketing and Market Access. With extensive experience in ophthalmology and a proven track record in launching therapies, Tozier is expected to enhance Outlook's commercialization strategies. The company anticipates submitting a Biologics License Application for ONS-5010, its ophthalmic formulation of bevacizumab, to the FDA in Q1 2022, aiming for potential approval and launch in late 2022 or early 2023. ONS-5010 could provide a safe alternative for retinal treatments currently reliant on unapproved formulations.
Outlook Therapeutics, Inc. (Nasdaq: OTLK) announced that Dr. Lawrence Lee will present pivotal Phase 3 data from the NORSE TWO trial on February 26, 2022, regarding ONS-5010, an investigational ophthalmic formulation of bevacizumab for treating wet AMD. The trial results indicated promising safety and efficacy, and if approved by the FDA, ONS-5010 could mitigate risks associated with off-label use of existing formulations. The presentation will take place at the RANZCO 52nd Annual Scientific Congress.